Company intelligence / Profile preview

Hunter-Fleming

Bristol, England, United Kingdomtmbears.com ↗

Ownership: Private
Development stage: Phase 2

Overview

At the time of its acquisition in 2008 by Newron Pharmaceuticals, Hunter-Fleming had a pipeline including three clinical-stage compounds and one discovery program. Lead asset HF0220 was in Phase II for Alzheimer’s disease with plans for a Phase II study in rheumatoid arthritis. Other assets included HF0420 (Phase I, prevention of anti-cancer therapy-induced neuropathy), HF0299 (Phase I, neuropathic pain), and HF1220 (discovery phase). No further independent clinical results are available post-acquisition.

Therapeutic areas: ImmunologyNeurology
Modalities: Small moleculeOligosaccharideSteroid
Industry: Biotech

Beyond the preview

Go deeper on Hunter-Fleming.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunter-Fleming.

Explore the full profile